Home › Targets › GLP-1 receptor

GLP-1 receptor (6 companies · 13 programs)

Companies with an active program directed at GLP-1 receptor.

Altimmune, Inc. ALT

pemvidutide — Metabolic Dysfunction-Associated Steatohepatitis Phase 2
pemvidutide — Alcohol Use Disorder Phase 2
pemvidutide — Alcohol-Associated Liver Disease Phase 2

Amylyx Pharmaceuticals, Inc. AMLX

avexitide — Post-Bariatric Hypoglycemia Phase 3
avexitide — Congenital Hyperinsulinism
AMX0318 — Post-Bariatric Hypoglycemia Preclinical

Viking Therapeutics, Inc. VKTX

VK2735 — Obesity Phase 3
VK2735 — Type 2 Diabetes Phase 3
VK2735 — Obesity Phase 2

vTv Therapeutics Inc. VTVT

TTP273 — Cystic Fibrosis-Related Diabetes Phase 2
TTP273 — Type 2 Diabetes Phase 2

Biomea Fusion, Inc. BMEA

BMF-650 — Obesity Phase 1

Vanda Pharmaceuticals Inc. VNDA

NEREUS — Nausea and Vomiting Phase 3